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Background: Children with respiratory tract infections are the single most frequent patient group to make use of
primary care health care resources. The use of antibiotics remains highly prevalent in young children, but can lead
to antimicrobial resistance as well as reinforcing the idea that parents should re-consult for similar symptoms. One
of the main drivers of indiscriminate antimicrobial use is the lack of evidence for, and therefore uncertainty
regarding, which children are at risk of poor outcome. This paper describes the protocol for the TARGET cohort
study, which aims to derive and validate a clinical prediction rule to identify children presenting to primary care
with respiratory tract infections who are at risk of hospitalisation.
Methods/design: The TARGET cohort study is a large, multicentre prospective observational study aiming to recruit
8,300 children aged ≥3 months and <16 years presenting to primary care with a cough and respiratory tract
infection symptoms from 4 study centres (Bristol, London, Oxford and Southampton). Following informed consent,
symptoms, signs and demographics will be measured. In around a quarter of children from the Bristol centre, a
single sweep, dual bacterial-viral throat swab will be taken and parents asked to complete a symptom diary until
the child is completely well or for 28 days, whichever is sooner. A review of medical notes including clinical history,
re-consultation and hospitalisations will be undertaken. Multivariable logistic regression will be used to identify the
independent clinical predictors of hospitalisation as well as the prognostic significance of upper respiratory tract
microbes. The clinical prediction rule will be internally validated using various methods including bootstrapping.
Discussion: The clinical prediction rule for hospitalisation has the potential to help identify a small group of
children for hospitalisation and a much larger group where hospitalisation is very unlikely and antibiotic prescribing
would be less warranted. This study will also be the largest natural history study to date of children presenting to
primary care with acute cough and respiratory tract infections, and will provide important information on symptom
duration, re-consultations and the microbiology of the upper respiratory tract.
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Respiratory tract infections (RTIs) in children present a
major resource implication for health care services inter-
nationally for four reasons. First, they are mostly managed
in primary care and are extremely common and costly to
service providers, families and employers [1,2]. Second,
there is clinical uncertainty in primary care regarding the
diagnosis and best management of RTIs, as reflected by
the variation in the use of antibiotics in primary care for
RTIs between nations [3], general practitioner (GP) prac-
tices [4] and clinicians [5,6]. Thirdly, antibiotic prescribing
by primary care clinicians in the UK is again on the rise
[7] and finally combined with the slowing in the deve-
lopment of new antibiotics, the overuse and misuse of
existing antibiotics is associated with the development and
proliferation of antimicrobial resistance between [8] and
within [9] nations as well as individuals [8-10]. The use of
antibiotics also leads to the subsequent ‘medicalisation of
illness’ in which patients believe they should consult for
similar symptoms in the future [11]. Thus, the increasing
or decreasing use of antibiotics can lead to vicious or vir-
tuous re-consultation cycles.
A number of key publications have highlighted the
need for more research to define the appropriate use
of antibiotics and health care resources for RTIs, if
the public health disaster of ineffective antibiotics for
serious infections is to be averted [12-15]. One par-
ticular focus was the requirement to establish which
clinical features of children presenting in primary
care with RTIs are associated with the development of
serious complications and the need for hospitalization
[16]. A prognostic tool identifying the risk of hospital-
isation could be a key driver to rationalising antibiotic
prescribing [17].
Clinical prediction rules are designed to reduce clin-
ical uncertainty in an outcome (such as a child’s risk of
hospitalisation) by assessing the strength of association
between the risk of it occurring and baseline character-
istics (for example, socio-demographic characteristics
or symptoms and signs of illness). Further insight
might be gained into the variability of the prognosis by
measuring bacterial and viral aetiology. For example,
co-infections of viral and bacterial pathogens may be
associated with poor prognosis [18-22]. To our know-
ledge, no study has characterised the bacterial and viral
flora of a representative sample of children presenting
with RTI to primary care, and investigated their prog-
nostic significance.
The aim of the TARGET cohort study is to establish the
clinical (signs and symptoms) and microbiological (viral
and bacterial pathogens) factors influencing the prognosis
of children presenting to primary care with acute cough
and RTI. This study is part of a wider programme of re-
search to improve the care of children with RTI including:(i) systematic reviews regarding the prognosis of RTI in
children and interventions to reduce antibiotic use [23,24]
and (ii) qualitative research into the consultation experiences
of parents and clinicians [25]. The final component of the
programme is to test the clinical and cost-effectiveness of a
fully developed clinical prediction rule based within a multi-
faceted intervention for children presenting to primary care
with acute RTI.
Methods/design
The TARGET cohort study is a multi-centre, prospect-
ive cohort study to derive and validate a clinical rule
using symptoms, signs, demographic and microbio-
logical factors to predict complications of acute cough
in children presenting to primary care with RTI. The
study is aiming to recruit 8,300 children from primary care
sites attached to four study centres (Bristol, London,
Oxford and Southampton, UK) between July 2011 and
end of June 2013. The Bristol study centre also collects
single sweep dual viral and bacterial throat swabs from
recruited children and asks parents/carers to complete a
symptom and medication diary for up to 28 days after re-
cruitment. The study was approved by the South West
Central Bristol Research Ethics Committee, UK (reference
number: 10/H0102/54) and research governance approvals
obtained across all areas prior to the start of recruitment
in those areas.
Participant eligibility
Children are included if they are: ≥3 months to <16 years;
present with a RTI with cough of ≤28 days duration prior
to consultation; presenting with illnesses such as asthma,
epilepsy or diabetes and RTI, including infective exacerba-
tion of asthma as well as children who require same day
hospital assessment or admission. Children are ex-
cluded if they present with acute, non-infective exacer-
bation of asthma; they present with RTI without cough
or cough of >28 days; they are considered to have a
high risk of serious infection (for example, immuno-
compromised, cystic fibrosis, splenectomy); they re-
quire a throat swab for the clinical care of the child
(Bristol centre only – see later for explanation); par-
ents/carers/children have temporarily registered with
the National Health Service (NHS) primary care site
(GP practice, Walk-in centres, GP Out of Hours centres
or polyclinics) and are likely to be unregistered/non-resi-
dent within a month; parent/carers/children are unable or
unwilling to assist with the study; they are already
recruited to the TARGET cohort study or involved in
other research or have recently (within 28 days) been in-
volved in similar clinical research. Figure 1 details the re-
cruitment process for participants.
The primary outcome, to be collected by a medical notes
review of all children, is any hospital admission for lower
No further data collection or baseline 
data use if consent form not received 
at Bristol study centre
On arrival at participating site parent/carer of children ≥3 months and <16 
years are identified by clinician and given information about the study
Clinicians record reasons for those children who declined to participate or 
whom they missed an opportunity to recruit
7, 14, 21, 28 day symptom diary
follow-up (or until cough resolved) by 
telephone by Bristol centre 
administrators (Bristol centre only)
Parent/carer & child see clinician who:
Answers questions about the study
Assesses eligibility
Initiates consent process
Records diagnostic & examination information
Gives symptom diary (Bristol centre only)
Takes throat swab (Bristol centre only)
Management according to usual 
clinical practice
30 day medical notes review
(for all children)
Parent/carer completes consent form 
and returns to clinician or to local study 
centre in FREEPOST envelope. Bristol 
study centre contacted if any questions 
regarding study or consent
CENTRAL LABORATORY
Custom made throat swabs (2 
polyurethane tipped swabs on plastic 
shafts with break points mounted on a 
single plug) transferred to special vials 
(bacterial - ∑ TRANSWAB liquid amies  
medium; viral - ∑ Virocult virus transport 
medium) and TARGET labels and 
packaging. 
Sent same day by next-day delivery 
Royal Mail SafeboxTM to central 
laboratory; viral throat swab transferred 
to HPA South West for analysis
Laboratory staff enter results on to 
web-based data system. Study team 
notified of results for research 
purposes only. 





Figure 1 TARGET cohort study recruitment process flowchart.
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in the 30 days following recruitment. Secondary outcomes,
collected in children recruited at the Bristol centre using a
parent completed symptom diary and medical notes re-
view are: referral from GP/Out of Hours to secondary
care; symptom duration and severity; re-consultations;antibiotic prescribing and antibiotic consumption in the
30 days following recruitment.
Clinician and participant recruitment
First, general practices express an interest in participat-
ing in the TARGET cohort study via the UK primary
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and prescribing clinicians (GPs or prescribing nurses) are
invited to sign up and complete agreement forms. Infor-
mation regarding the total patient list size as well as the
number of children in the eligibility age range are
obtained. By agreement with the study centre, individual
sites are able to organise recruitment to suit the needs of
the organisation; for example, sites can enlist the support
of their practice nurses to help with recruitment.
Only clinicians who self-report use of antibiotics in
30% or fewer children with RTIs are invited to recruit.
This criterion was set to reduce the effect of what is known
as ‘confounding by indication’. This is the phenomenon
whereby the way primary care clinicians already decide to
which children they will prescribe antibiotics is to an ex-
tent associated with any clinical prediction tool that might
be developed. This plausible possibility will of course in it-
self alter the risk of the hospitalisation outcome amongst
children in the study, and hence in turn reduce the appar-
ent associations between some risk factors and the out-
come. In addition, in order to ensure an unbiased sample
of the full illness spectrum, clinicians are asked to identify
a systematic recruitment strategy. Clinicians are asked to
specify how many children per week they expect to recruit.
To measure the success of clinicians’ recruitment strat-
egies, and to establish the generalisability of recruited chil-
dren to the population as a whole, clinicians are asked to
complete some brief details on those children that they
invited to participate but declined and those they
missed. Clinicians are asked to use the online database
or complete and send postcards to record the child’s
illness severity and the reason for decline or missed
opportunity to recruit. A ‘missed’ opportunity to re-
cruit is defined as those children who would have nor-
mally met the clinician’s own strategy criteria and the
study inclusion criteria but where the clinician decided
not to recruit for whatever reason (for instance, the
clinician forgot or was too busy).
All clinicians are trained in the study processes of
obtaining consent, assent (for children aged 11 and
over) and completing the baseline data collection form
known as the case report form (CRF). For the clini-
cians recruiting children to the Bristol study centre,
clinicians are additionally trained in how to take a ‘sin-
gle sweep’ dual bacterial-viral TARGET specific throat
swab. A video (see http://www.youtube.com/watch?v=
eiM0arJGYT0&feature=youtu.be) was created to illus-
trate and standardise the taking and packaging of the
throat swab to send to the local laboratory for process-
ing. After training in the study recruitment processes,
clinicians are given participant study packs, vial stands,
practice and clinician instruction folders and clinician
specific logon details for the online study database and
are able to commence recruitment.Data collection
Baseline case report form
Once informed consent (and assent for children aged 11
or over) has been obtained, recruiting clinicians complete
a CRF (see Additional file 1) for each child to record
socio-demographic information, carer-reported symptoms
(including duration and severity of symptoms in the past
24 hours), clinician observed signs and clinical manage-
ment data, and treatment (such as no, delayed or immedi-
ate antibiotic prescription).
Microbiological data (Bristol study centre children only)
Throat swab design and transport
Bristol centre research staff in collaboration with the
throat swab manufacturer, Medical Wire Ltd (Wiltshire,
UK) designed a kit consisting of a dual bacterial-viral
throat swab suitable for use in small children, requiring
one sweep either side of the child’s throat.
The swab kit contains the two swabs (two polyurethane
foam tipped swabs on plastic shafts with break points,
mounted on a single plug (swab tip 15mm, shaft 110mm,
handle 30mm) and clear plastic 13mm diameter 84mm
long tubes, one with a purple cap for bacteriology testing
(containing ∑ TRANSWAB liquid Amies medium) and
one with a green cap for virology testing (containing ∑
Virocult virus transport medium and 3 plastic beads). The
kit is provided in a sterile peel pouch.
Once the recruiting clinician has taken the throat swab,
swabs are individually broken off into the vials in line with
standardised instructions. Throat swabs are sent, using a
next-day delivery Post Office Safebox™ to the Bristol Centre
for Antimicrobial Research and Evaluation (BCARE) at
Southmead Hospital, Bristol, UK (bacteriology) from
where the virology swab is forwarded to the Specialist
Virology Centre at the South West Health Protection
Agency (HPA) Laboratory, Bristol UK (virology).
Processing of bacterial swabs
The bacteriological swab is vortex mixed and the transport
medium is innoculated onto agar plates using both standard
streaking method and spiral plating. Following overnight in-
cubation of the agar plates, colonies morphologically consist-
ent with Streptococcus pneumoniae, Haemophilus influenzae,
Moraxella catarrhalis, beta haemolytic streptococci (A, C, F,
G), or Staphylocococcus aureus are identified by standard la-
boratory tests. For each sample, the presence or absence of
these target organisms is recorded along with a semi-
quantitative colony count (from the streak plates) and a
quantitative colony count (from the spiral plates). Total aer-
obic bacterial count is also recorded.
Processing of viral swabs
On receipt of the virology swab sample, the virology lab
staff test the sample for common respiratory viruses
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have been extensively validated and quality assured for rou-
tine viral diagnosis. A 0.1mL aliquot of transport medium
from each swab sample is processed to recover microbial
nucleic acids using a robotic nucleic acid extraction method.
Real-time PCR assays are used to detect the presence or
absence of the following viruses and bacteria: influenza
A and B, respiratory syncytial viruses, metapneumoviruses,
parainfluenzavirus types 1–4, adenovirus, rhinovirus, entero-
virus, parechovirus, coronavirus, bocavirus, Bordetella per-
tussis, Bordetella parapertussis, Mycoplasma pneumoniae
and Chlamydia pneumoniae.
Results of throat swabs
The microbial results of the samples are not made avail-
able to the recruiting clinicians because this could influ-
ence the subsequent care of the child (this is also the
reason for excluding children where the clinician feels a
throat swab is necessary for clinical management). Add-
itionally, throat swabs are rarely taken in routine clinical
care for children with cough and the clinical significance
of the results is not established.
Symptom diary (Bristol study centre children only)
Parents/carers are asked to complete a symptom diary,
based on a previously validated study diary [26], either on
paper or online until symptom resolution or day 28, which-
ever is soonest. This is supported by weekly telephone con-
tact, similar to that successfully used to obtain >85% follow
up data in previous studies [27,28], to record symptom
duration, severity and medicine consumption. Parents/
carers are also invited to answer some simple background
information questions to establish whether the study
is representative of the UK population as a whole.
Standardised study procedures are used to manage,
implement and record the outcomes of the daily tele-
phone calls to support recruited families in completing
the diary. Several processes and strategies (including
voicemail messages, short message service (SMS) text
messages and postcard reminders) are utilised to maxi-
mise diary completion and return.
Primary care notes review
30 day primary care notes review
The primary care records of all children are examined for
hospital admissions and primary care re-consultations in
the 30 days following recruitment. Information on prior
immunisations and antibiotics, are also collected from the
primary care record. Primary care notes reviews com-
mence at least 3 months after the date the child was
recruited, in order to allow hospital discharge letters to
reach the primary care notes. Double notes reviewing is
undertaken for 1% of the participants to estimate inter-
reviewer error.Secondary care notes review
Since primary care discharge summaries do not always
contain full details of hospitalisations, for the anticipated
160 children (40 per centre) identified with a hospital
admission, secondary care records will be examined for
lower RTIs (such as ‘chest infection’, bronchitis, bron-
chiolitis, pneumonia, lung abscess or empyema) requir-
ing interventions available only in hospital (including
oxygen, intravenous fluids or intravenous antibiotics).
Data management systems
A large study such as this requires highly efficient data
management systems. All data for the study are collected
on either web-based or paper forms. The web-based data
collection and management system was created by the
Bristol and London teams, with input from all centres
and collaborators. As a time-saving facility, when a
recruiting clinician completes the CRF as an online
form, a summary of the data collected is created for the
clinician to copy and paste into the recruited child’s
medical record. The symptom diary is available for Bris-
tol centre parents to complete online. Parents/carers ac-
cess their child’s online symptom diary by entering the
child’s study identification number and date of birth.
Only parents/carers who have completed a valid consent
form can use this facility. Each study centre has an MS
Access (Microsoft, US) database, which facilitates pri-
mary care site, recruiting clinician, and notes review
management. The Bristol study centre holds a combined
version, updated at least weekly, so that weekly recruit-
ment and notes review completion monitoring summar-
ies are produced and reviewed.
Service user involvement
Parents have been consulted throughout the whole
process of the study to inform design, conduct and data
collection, including preparation of the study paperwork
and marketing materials for the recruitment phase, feasi-
bility of the dual throat swabs and design and use of the
symptom diary on paper and online. 13 different inde-
pendent parents gave feedback on a variety of different
aspects of the study and at least 20 different children of
various ages provided feedback on study aspects involv-




With a 5% two-sided significance level and 80% power, as-
suming a hospitalisation rate of 2% [29,30] and an individ-
ual clinical characteristic prevalence of 25% [29], a sample
of 2,588 will allow detection of an odds ratio (OR) of 2.4 of
associated signs and symptoms (ORs of between 2.5 and 5
have been observed previously [29,31]). If hospitalisation
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a sample of 2,390 will allow detection of an odds ratio of
4.5 for associated signs and symptoms (assuming the out-
come is hospitalisation and the exposure is the presence of
a given clinical characteristic). Taking account of the need
to collect derivation and validation data (and dividing the
dataset in a 50:50 split, an antibiotic prescribing rate of
30% (these children will not be included in the analyses
due to the potential for confounding by indication) and
10% attrition, a total sample of 8,216 will be required. This
sample size will also give more scope to look at several var-
iables (maximum one variable for every 10 hospitalised
cases) [32] in the multivariable regression model.
With a 5% two-sided significance level and 80% power,
assuming a mixed viral and bacterial infection rate of
10% [33], a sample of 1,610 children will be needed to
detect the 10% of children with the most prolonged/se-
verest symptoms with an OR of 2. Allowing for symp-
tom diary and microbiological data loss in 15%, 1,894
children are required to be recruited from the Bristol
centre (sub-set of children).
Statistical analysis
The main statistical analyses will be carried out according
to the study analysis plan. First, descriptive statistics will
be used for: children’s clinical and microbiological charac-
teristics; hospitalisations; symptom duration and severity;
and primary care re-consultations; immunisation and anti-
biotic exposures pre-recruitment; antibiotic prescribing
and consumption. For outcomes such as hospitalisation,
re-consultation, lengthy symptom duration and antibiotic
prescribing testing will include chi-square for categorical
variables (or Fisher’s exact test when the expected cell is
less than 5) and both a parametric and non-parametric ap-
proach for continuous variables depending on the nature
of the distribution. Internal validation will be used for
assessing the value of a derived rule [34]. We will also ex-
plore alternative approaches including bootstrapping and
subdivision of the sample on a selective rather than a ran-
dom basis so as to assess the robustness of the rule in dif-
ferent circumstances (such as geographical location). The
clinical prediction rule will be developed based on the lin-
ear predictor in a logistic regression model in which the
outcome variable is hospitalisation among children not
treated with antibiotics. Candidate prognostic variables
will be categorised into demographic background, and
symptoms and signs (for example, overall illness severity,
fever, shortness of breath). Variables included in logistic
regression models will be based on an ‘inclusive’ p-value
threshold of 0.1 in the univariable analysis. Significance in
the multivariable model will take into account the number
of variables tested using multiple testing methods such as
the Bonferroni Correction. We will check for nonlinear ef-
fects of continuous variables, and will examine candidateinteractions specified a priori. Such effects will be included
in the final models as necessary. We will begin by examin-
ing the predictive value (based on diagnostic odds ratios
and confidence interval (CI) statistics) of the best predic-
tors from the socio-demographic variables. We will then
examine the additional prognostic value of presenting signs
and symptoms (compared with socio-demographic data
alone).
Diagnostic and prognostic models that are developed
using p-value-based variable selection will inevitably suf-
fer from statistical over-optimism. Therefore, the final
models will be validated using the second dataset, and
the published decision rule will be based on the linear
predictors from the model re-estimated in this validation
dataset. In the final stages of analysis, we will examine
the sensitivity and specificity of the linear predictor,
based on a set of chosen thresholds for positivity. A
comparison will be made between the results obtained
from the validation and the use of shrinkage based ap-
proaches applied to the original development dataset
[35]. The final clinical rule will be characterised based
on its sensitivity and specificity, and positive and nega-
tive predictive values.
Univariable and multivariable logistic regression models
will also be used to investigate the unadjusted and adjusted
strengths of association between the presence/absence of
co-viral/bacterial carriage and prolonged symptoms. Model
entry will be set with a threshold p-value of 0.1, a clinically
informed (rather than automated stepwise) selection pro-
cedure will be used and the potential interaction of pre-
dictor variables, in particular any interaction between
specific symptoms, will be tested. In addition, we will
explore the effects of the semi-quantitative bacteri-
ology (scanty, moderate and heavy growth of target or-
ganisms) and virology (real time PCR cycle threshold
of detection (Ct value)) on symptom duration and we
will investigate interactions between the bacteriology
and antibiotic treatment.
Discussion
The TARGET study is, to our knowledge, the first study
primarily designed to improve the targeting of antibi-
otics via the development of a clinical prediction rule for
appropriate antibiotic prescribing in children presenting
to primary care with acute cough. This study addresses
repeated calls from policymakers and the research com-
munity to appropriately target the use of resources in
RTIs, and attempts to address the ‘ticking timebomb’ of
antibiotic resistance [12-15]. As one of the most frequent
users of primary care, there is a need for more appropri-
ate, evidence-based antibiotic prescribing to reduce un-
necessary antimicrobial resistance and to reduce the
expectation of parents to consult and receive antibiotics
for cough.
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the large scale of the design. We aim to recruit at least
8,300 children across 4 study centres, thereby
maximising the potential for generalisability. This study
will be the largest natural history study to date of chil-
dren presenting to primary care with acute cough and
RTI, providing important data on symptoms and signs
presented in primary care, re-consultations and
hospitalised cases. In a subset of children, symptom se-
verity, duration and a broad panel of potential respira-
tory pathogens of the upper respiratory tract will be
made available. The main challenge in this study will be
the ambitious recruitment targets necessitated by the
rarity of the outcome; hospitalisation is an infrequent
event in RTIs occurring in 1-2% of those presenting to
primary care [29].
The potential for a tool to help clinicians to decide
whether a child presenting with RTI requires hospitalisa-
tion is highly desirable although relatively speaking this
is a rare event in the day-to-day practice of an individual
clinician. Perhaps of more benefit is a tool that can dis-
tinguish a much larger population of children that not
only do not need to be hospitalised but could avoid anti-
biotics. A clinical prediction tool could potentially de-
liver both and is thus worth the effort of such a large
and complex study.
In summary, the TARGET study will be one of the lar-
gest studies of its kind undertaken in primary care. The
anticipated prediction rule aims to improve the targeting
of antibiotics for those children who are most likely to
benefit, whilst also identifying those children where
treatment is unlikely to be required. This will provide
much needed guidance for the frequently encountered
conundrum of appropriate management of children pre-
senting to primary care with RTIs.
Additional file
Additional file 1: The TARGET cohort study case report form (CRF).
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